Trastuzumab deruxtecan with immunotherapy before surgery for early breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a combination of two drugs (trastuzumab deruxtecan and an immunotherapy) given before surgery to shrink early-stage breast cancer tumors. It is for people whose tumors have low levels of HER2 and are hormone receptor positive.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have not had treatment for this breast cancer yet.
- Your tumor is larger than 2 cm or has spread to lymph nodes, but has not spread to distant organs.
- Your tumor has low HER2 levels (IHC 1+ or IHC 2+ with negative FISH).
- Your tumor is hormone receptor positive (estrogen and/or progesterone positive).
- You are willing to have surgery after the neoadjuvant therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares giving trastuzumab-deruxtecan before surgery versus standard chemotherapy plus trastuzumab and pertuzumab. It aims to see which approach works better to shrink or control HER2-positive early breast cancer and improve outcomes.
This trial tests a targeted antibody-drug medicine (trastuzumab deruxtecan, T-DXd) in people with metastatic breast cancer that is HER2-low or HER2 IHC 0. It may help by treating tumors that haven’t previously received anti-HER2 treatment in the metastatic setting.
This Phase 2 study compares trastuzumab deruxtecan to standard chemotherapy given before surgery for HER2-positive breast cancer. It aims to see which treatment works better to shrink the tumor and spread before the operation.
This trial tests a targeted drug, trastuzumab deruxtecan, for people with non-small cell lung cancer that has a specific HER2 gene change. The treatment is given before surgery to shrink the tumor and make it easier to remove.
This Phase 2 study tests whether trastuzumab deruxtecan alone or combined with anastrozole can control early-stage breast cancer that is HER2-low and hormone-receptor positive. It aims to improve outcomes after initial surgical treatment by targeting cancer cells that may have low levels of HER2.
This study follows women with advanced breast cancer (metastatic) who have hormone-receptor positive tumors and low HER2 levels, to see how well a new drug called Trastuzumab Deruxtecan works when used in routine clinical care after prior hormone therapy.
Hear when a new HER2-low Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.